#########

#########
Volume 8, Number 28
Monday, July 28, 2008
#########



In this issue: (click heading to view article)
#########
######### ######### Acquisition of VKC and AKC After Bone Marrow Transplantation
#########
######### ######### Predicting Visual Outcome Following Retinectomy for Retinal Detachment
#########
######### ######### PERGs and Visual Evoked Potentials in Retinitis Pigmentosa
#########
######### ######### Evaluation of Threshold Estimation and Learning Effect of SITA Fast and CLIP in Damaged Visual Fields
#########
######### ######### Briefly





http://www.raveonhs.com/520/






Acquisition of VKC and AKC After Bone Marrow Transplantation

Vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) result from genetic and environmental factors. Researchers in Saudi Arabia, in conjunction with the Johns Hopkins University School of Medicine, conducted this observational case series in which patients who had no history of atopic disorders before bone marrow transplantation (BMT) seemed to have acquired VKC or AKC from their donors, who had atopic disorders.

The patients in this study were part of a cohort of 621 patients who had undergone allogeneic hemapoietic stem cell transplantation (HSCT) from January 1997 through December 2007. Each patient underwent complete ophthalmologic examination, determination of the total serum immunoglobulin (Ig)E and conjunctival scrapings.

Four (0.64 percent) of the 621 patients who had undergone HSCT acquired VKC or AKC after BMT. The donors for these four patients had VKC or atopic dermatitis. In addition, two of these four patients developed asthma, and one had elevated total serum IgE. Conjunctival scrapings of all four patients revealed the presence of eosinophils. One patient had concurrent graft-versus-host disease.

The study results suggest the possibility of the acquisition of VKC or AKC after BMT by adoptive transfer.

SOURCE: Tabbara KF, Nassar A, Ahmed SO, et al. Acquisition of vernal and atopic keratoconjunctivitis after bone marrow transplantation. Am J Ophthalmol 2008; Jul 7 [Epub ahead of print].
Table of Contents






Predicting Visual Outcome Following Retinectomy for Retinal Detachment

In this study, investigators at London's Moorfields Eye Hospital evaluated patient outcomes following retinectomy surgery to identify factors that predict visual outcome.

The retrospective, uncontrolled interventional case series included patients who underwent retinectomy surgery at Moorfields during a two-year period. Researchers recorded peri-operative factors that had the potential to influence functional outcome, including etiology of retinal detachment, type of ocular trauma, preoperative visual acuity and IOP, grade of proliferative vitreoretinopathy (PVR), extent and position of retinectomy, peri-operative complications, tamponade agent and prophylactic 360 degrees laser retinopexy.

A total of 145 patients underwent retinectomy surgery. After a mean follow-up period of 23.2 months (6 to 58 months) 16 percent of eyes in this group had visual acuity of 20/60 or better, 33 percent had visual acuity of between 20/60 and 20/400 and 51 percent had visual acuity worse than 20/400. Visual acuity was improved or stable in 76 percent of eyes, and the rate of complete retinal reattachment was 68 percent. For each step-wise increase in the grade of PVR, results showed an approximately 15 percent increased risk of final visual acuity of worse than 20/40. The use of additional 360-degree prophylactic laser retinopexy prior to removing silicone oil was associated with a higher rate of final retinal reattachment.

Based on the results, the authors maintain that retinectomy is a valuable technique in managing complex retinal detachment, but is associated with a significant risk of retinal redetachment and poor visual outcome.

SOURCE: de Silva DJ, Kwan A, Bunce C, Bainbridge J. Predicting visual outcome following retinectomy for retinal detachment. Br J Ophthalmol 2008;92(7):954-958.
Table of Contents






PERGs and Visual Evoked Potentials in Retinitis Pigmentosa

Hungarian researchers aimed to analyze pattern electroretinograms (PERGs) and pattern visual evoked potentials (PVEPs) in retinitis pigmentosa (RP) patients.

In this study, PERGs and PVEPs were recorded in 106 eyes of 53 RP patients. Researchers used a RETIport system for stimulation and recording. Reproducible PERGs were found in 17 of the patients (32 percent), from only one eye in 4 of the 17 patients. Normal PERGs were not detected in any patient; all 53 patients gave reproducible PVEPs. Based on these results, the patients could be divided into three groups according to the waveform of the response. In the first group (17 participants), all patients produced PVEPs with a characteristic triphasic shape but with smaller amplitudes. In the second group (16 participants), the PVEPs displayed doubled P100 peaks, with components separated by about 50 ms. The recordings in the third group (20 participants) were broad in shape and characterized by a greatly increased N70-N170 latency difference and decreased amplitudes.

The authors suggest that the appearance of both the responses with decreased amplitude and those with broad, doubled P100 waves might reflect differences in central retinal degeneration. They believe that the significance and pathological background of these PVEP alterations require further investigation.

SOURCE: Janáky M, Pálffy A, Horvath G, et al. Pattern-reversal electroretinograms and visual evoked potentials in retinitis pigmentosa. Doc Ophthalmol 2008;117(1):27-36.
Table of Contents






Evaluation of Threshold Estimation and Learning Effect of SITA Fast and CLIP in Damaged Visual Fields

In this study, Genoan researchers evaluated the threshold estimation, learning effect and between-algorithm differences in damaged visual fields of the Fast Swedish Interactive Thresholding Algorithm (SITA Fast), the Humphrey Field Analyzer (HFA) and the Continuous Light Increment Perimetry (CLIP) strategy of the Oculus Twinfield perimeter.

Twenty-one glaucomatous patients with damaged visual fields (MD worse than -8 dB) underwent Oculus Full Threshold (FT), Humphrey FT, SITA Fast and CLIP 30-2 perimetric examinations. All tests were repeated in a second session at least three days later. The point-wise differences in absolute sensitivity and of the total deviation plot values between FT and fast algorithms, between fast algorithms and the learning effect were evaluated (Wilcoxon test and Bland-Altman analysis).

The average point-wise sensitivity difference between SITA Fast and HFA FT strategy (0.84 dB) was significantly lower than that found between CLIP and Oculus FT strategy (1.71 dB). Between-algorithm point-wise differences of the total deviation plot values of the fast strategies were not significantly different. Learning effect for SITA Fast (0.67 dB) was higher than that found for CLIP (0.39 dB). Test time for SITA (367 ± 71 sec) and CLIP (453 ± 98 sec) were about 55 percent and 35 percent, respectively; both shorter than those found with FT algorithms. The acceptance for fast algorithms and particularly for CLIP was significantly better.

The study authors concluded that the two fast strategies, even though they used very different algorithms, showed good threshold estimation compared to FT strategies, with a consistent time saving in damaged visual fields.

SOURCE: Capris P, Autuori S, Capris E, Papadia M. Evaluation of threshold estimation and learning effect of two perimetric strategies, SITA Fast and CLIP, in damaged visual fields. Eur J Ophthalmol 2008;18(2):182-90.
Table of Contents





BRIEFLY
  • FDA APPROVES MARKETING OF B&L'S CRYSTALENS HD IOL. The FDA has granted approval to Bausch & Lomb to market the company's Crystalens HD in the United States. The IOL was first approved by the FDA in November 2003; the Crystalens HD is the fourth generation of the accommodating lens. The surface of the Crystalens HD has been shaped to enhance depth of focus with a proprietary optical modification designed to improve near vision without compromising intermediate or distance vision and without inducing increased undesirable dysphotopsia or night vision symptoms. A total of 125 primary eyes were implanted with the Crystalens HD in patients who had a visually significant cataract, < 1.00 D of corneal astigmatism and the potential for best corrected visual acuity (BCVA) of 20/25 or better in both eyes. Of these patients, 80 percent reported vision at J2 or better at four months. Bausch & Lomb officials say that surgeons will be instructed to continue using the same surgical protocols for the Crystalens HD as they have used in past generations of the lens.
  • HYALURONIC ACID IN THE BODY MAY PROVIDE NATURAL CONTACT LENS MOISTURIZING AGENT. Chemical engineering researchers at Ontario's McMaster University School of Biomedical Engineering have shown that hyaluronic acid commonly found in the body can be used as a natural moisturizing agent for contact lenses in place of the synthetic materials currently used. The research, which was recently published in the journal Biomaterials, showed that hyaluronic acid can be trapped in existing contact lens material without affecting optical properties. Investigators also discovered that using hyaluronic acid considerably reduced the buildup of proteins that can cloud contact lens material—the cause of up to 30 percent of all after-care visits by contact lens wearers to optometrists. Hyaluronic acid is a natural polymer that reduces friction. A person weighing about 155 pounds has about 15 g (roughly 0.5 oz.) of hyaluronic acid in his or her body, one-third of which is "recycled" daily. The body uses the substance to repair skin, provide resiliency in cartilage and contribute to the growth and movement of cells. It is also used by the medical profession to treat patients with dry eyes, in cataract surgery and for other eye-related procedures. Manufacturers have not yet produced contact lenses with hyaluronic acid, but the authors of this study believe that it's possible. "We've shown that the process works," says study author Heather Sheardown, professor of chemical engineering at McMaster and a member of the McMaster School of Biomedical Engineering. "We're optimistic that a manufacturer will see the benefits of using this naturally based technology to provide contact lens wearers with greater comfort and convenience."

  • EYECYTE RECEIVES FUNDING FROM PFIZER FOR RETINAL DISEASE RESEARCH. EyeCyte, Inc., an early-stage stem/progenitor cell-based ophthalmology research and development company, has received funding through an agreement with Pfizer to drive product development of technology applications to treat diabetic retinopathy (DR) and other retinal diseases. The company will be building on research into causes of and potential treatments for retinal disease by the Scripps Research Institute. EyeCyte will use the properties of blood- and bone marrow-derived progenitor cells of patients to pursue the development of treatments for acquired and inherited retinal diseases, including DR, retinopathy of prematurity, retinal vascular occlusive disease, AMD and retinitis pigmentosa. Under the terms of the agreement, Pfizer will have right of first refusal for a buyout of EyeCyte or its technologies.


Table of Contents

 





#########
#########
 Check Yearly. See Clearly. Open Your Eyes To the Opportunities.
The Check Yearly. See Clearly.(SM) marketing campaign is opening consumers' eyes to the benefits of regular eye exams. Call the Vision Council of America at 800-424-8422 today or visit checkyearly.com for your free promotional materials.
#########
#########